Cytomed Therapeutics LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
SCHEDULE 13G/A: mDR Limited Amends Beneficial Ownership in CytoMed Therapeutics, Retaining 11.33% Stake
mDR Limited has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 11.33% in CytoMed Therapeutics Ltd, following a minor share sale.
NASDAQ
28 Consultants Ltd has disclosed a beneficial ownership of 7.62% in CytoMed Therapeutics Ltd, holding 880,313 Ordinary Shares.